Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below Fifty Day Moving Average – Here’s What Happened

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $4.53 and traded as low as $3.91. Voyager Therapeutics shares last traded at $4.03, with a volume of 434,192 shares.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Voyager Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Finally, HC Wainwright reduced their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $12.12.

Voyager Therapeutics Price Performance

The firm has a market cap of $224.07 million, a PE ratio of -1.87 and a beta of 0.95. The company’s 50 day moving average price is $4.53 and its 200 day moving average price is $3.77.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, November 10th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.06. The company had revenue of $11.15 million for the quarter, compared to analyst estimates of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. Sell-side analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, CFO Nathan D. Jorgensen sold 7,666 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $4.78, for a total transaction of $36,643.48. Following the sale, the chief financial officer owned 123,834 shares in the company, valued at $591,926.52. This represents a 5.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.39% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC raised its holdings in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company’s stock valued at $35,000 after acquiring an additional 9,376 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at $36,000. Wexford Capital LP purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter worth $42,000. R Squared Ltd purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter worth $48,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Voyager Therapeutics during the second quarter worth $50,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.